TINTON FALLS — The 2010 Norman J Field Lecture in Science, “Preventing Alzheimer’s Disease by 2020?,” will be presented by Dr. Zaven S. Khachaturian Thursday, Oct

Joyce Finkle and Mary Shirley say being part of the Alzheimer’s community can sometimes be described as being on an emotional roller coaster.

The first trial of a new model for testing Alzheimer’s treatments has reassured researchers that a promising class of drugs does not exacerbate the disease if treatment is interrupted.

Washington, May 26 : High levels of a protein, called GGA3, could prevent the accumulation of an enzyme linked to Alzheimer’s, found researchers at Tufts University School of Medicine.

Researchers at Tufts University School of Medicine have zeroed in on a protein that may play a role in the progression of Alzheimer’s disease.

Researchers at Tufts University School of Medicine have zeroed in on a protein that may play a role in the progression of Alzheimer’s disease. The team found that increasing levels of the protein (called GGA3) prevented the accumulation of an enzyme linked to Alzheimer’s.

April 29, 2010 - Using a new mouse model of Alzheimer’s disease, researchers at Mount Sinai School of Medicine report to have found that Alzheimer’s pathology originates in Amyloid-Beta (Abeta) oligomers in the brain, rather than the amyloid plaques previously thought by many researchers to cause the disease.

April 28, 2010 - Older adults with evidence of amyloid in the brain but no clinical symptoms of Alzheimers disease have structures in the brain that dont communicate readily with each other, according to researchers at Washington University School of Medicine in St. Louis.

Using a new mouse model of Alzheimer’s disease, researchers at Mount Sinai School of Medicine have found that Alzheimer’s pathology originates in Amyloid-Beta (Abeta) oligomers in the brain, rather than the amyloid plaques previously thought by many researchers to cause the disease.

Researchers at NYU School of Medicine have found that elevated cerebrospinal fluid levels of phosphorylated tau231 (P-tau231), a damaged tau protein found in patients with Alzheimer’s disease, may be an early diagnostic biomarker for Alzheimer’s disease in healthy adults.The study published this month online by Neurobiology of Aging shows that high levels of P- tau231 predict future memory …

The 17th annual event, sponsored by Alzheimer’s Services of the Capital Area, will have a theme of “Diagnosis and Beyond.” WHEN: Wednesday, March 3, 8:30 a.m. to 4 p.m.

Researchers at NYU School of Medicine have found that elevated cerebrospinal fluid levels of phosphorylated tau231 (P-tau231), a damaged tau protein found in patients with Alzheimer’s disease, may be an early diagnostic biomarker for Alzheimer’s disease in healthy adults. The study published this month online by Neurobiology of Aging shows that high levels of P- tau231 predict future memory …

Researchers at NYU School of Medicine have found that elevated cerebrospinal fluid levels of phosphorylated tau231 (P-tau231), a damaged tau protein found in patients with Alzheimer’s disease, may be an early diagnostic biomarker for Alzheimer’s disease in healthy adults.

Researchers Link Elevated Level of Protein to Memory Loss, Decreased Gray Matter

Cognitive fluctuations, or episodes when train of thought temporarily is lost, are more likely to occur in older persons who are developing Alzheimer’s disease than in their healthy peers, according to scientists at Washington University School of Medicine in St.

Cognitive fluctuations, or episodes when train of thought temporarily is lost, are more likely to occur in older persons who are developing Alzheimer’s disease than in their healthy peers, according to scientists at Washington University School of Medicine in St. Louis. Cognitive fluctuations include excessive daytime sleepiness, staring into space and disorganized or illogical thinking.

Cognitive fluctuations, or episodes when train of thought temporarily is lost, are more likely to occur in older persons who are developing Alzheimer’s disease than in their healthy peers, according to scientists at Washington University School of Medicine in St. Louis.

Cognitive fluctuations, or episodes when train of thought temporarily is lost, are more likely to occur in older persons who are developing Alzheimer’s disease than in their healthy peers, according to scientists at Washington University School of Medicine in St. Louis.

Cognitive fluctuations, or episodes when train of thought temporarily is lost, are more likely to occur in older persons who are developing Alzheimer’s disease than in their healthy peers, according to scientists at Washington University School of Medicine in St. Louis.

Current Alzheimer’s disease (AD) research indicates that accumulation of amyloid-beta (Aβ) protein plaques in the brain is central to the development of AD. Unfortunately, presence of these plaques is typically confirmed only at autopsy. In a special issue of the journal Behavioural Neurology, researchers review the evidence that Positron Emission Tomography (PET) can image these plaques during …